We are ethyl 4-chlorobutanoate CAS:3153-36-4 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
Chemical Name: ethyl 4-chlorobutanoate
4-chloro-butyric acid ethyl ester
Butanoic acid, 4-chloro-, ethyl ester;
4-Chlorobutyric Acid Ethyl Ester
Butyric acid,4-chloro-,ethyl ester
4-chlorobutanoic acid ethyl ester
Butanoic acid,4-chloro-,ethyl ester
4-chloro-3-oxobutyric acid ethyl ester
Molecular Formula: C6H11ClO2
Molecular Weight: 150.60300
Physical and Chemical Properties:
Density: 1.075 g / mL at 25 ° C (lit.)
Boiling point: 186 ° C (lit.)
Melting point: -70ºC
Flash point: 125 ° F
Refractive index: n20 / D 1.432 (lit.)
Appearance:Clear yellow to brownish liquid
Moisture Content: ≤0.2%
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Keep away from heat, sparks, and flame. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Corrosives area.
Application:An important raw material and intermediate used in Organic Synthesis,Pharmaceuticals.
Related News: In 2016, in order to promote the innovative development, transformation and upgrading of the pharmaceutical industry, the Development and Reform Commission led the compilation of the “Guiding Opinions on Promoting the Healthy Development of the Pharmaceutical Industry”, which put forward requirements for all aspects of the medical industry and specifically proposed support for the field of chemical raw materials. .29882-07-3 As United Airlines said when suspended flights to Beijing, Shanghai and Chengdu, the decision was made “due to the continued drop in demand for travel to China and the US Department of State’s decision to raise its China travel advisory to a Level 4.”indan-1-one CAS:83-33-0 Further research on Oligomannate’s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement.Propionyl chloride Further research on Oligomannate’s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement.Dr. John K. Westwick, CEO of Resonant, added “Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates.